Home » Topics » Regulatory » EMA

EMA
RSS

Pfizer reflects on milestones of fourth quarter 2017

Feb. 5, 2018

EMA committee recommends approval of biosimilar insulin glargine Semglee

Jan. 31, 2018

EMA committee recommends approval of use of Ameluz with daylight PDT

Jan. 31, 2018

Rexgenero receives ATMP certificate from EMA for REX-001

Jan. 31, 2018

EMA committee recommends approval of Lamzede for alpha-mannosidosis

Jan. 30, 2018

EMA committee hands down negative opinion for enclomiphene MAA

Jan. 29, 2018

EMA committee recommends approval of Hemlibra in hemophilia A

Jan. 29, 2018

CHMP supports approval of Shingrix for prevention of shingles in adults aged 50 and over

Jan. 29, 2018

CHMP grants positive opinion for labeling update to Relvar Ellipta in patients with asthma

Jan. 29, 2018

EMA accepts patisiran MAA for hereditary ATTR amyloidosis

Jan. 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...